

REFERENCES

- Angelopoulou K. and Diamandis EP. Detection of TP53 tumor suppressor gene product and p53 auto-antibodies in the ascites fluid of women with ovarian cancer. *Eur J Cancer* 1997; 33: 115–21.
- Angelopoulou K and Diamandis EP. Quantification of antibodies against the p53 tumor suppressor gene product in the serum of cancer patients. *Cancer J* 1993; 6: 315–21.
- Angelopoulou K., Rosen B., Stratis M., et al. Circulating antibodies against p53 protein in ovarian cancer: correlation with clinicopathological features and survival. *Cancer* 1996; 77: 2146–52.
- Angelopoulou K., Diamandis E. P., Sutherland D. J. A., et al. Prevalence of serum antibodies against the p53 tumor suppressor gene protein in various cancers. *Int. J. Cancer*, 58: 480-487, 1994.
- Angelopoulou K., Stratis M., Diamandis E. P. Humoral immune response against p53 protein in patients with colorectal carcinoma. *Int. J. Cancer*, 70: 46-51, 1997.
- Bennett W. P., Colby T. V., Travis W. D., et al. p53 protein accumulates frequently in early bronchial neoplasia. *Cancer Res.*, 53: 4817-4822, 1993.
- Bourhis J., Lubin R., Roche B., et al. Analysis of p53 serum antibodies in patients with head and neck squamous cell carcinoma. *J. Natl. Cancer Inst.*, 88: 1228-1233, 1996.

- Bubb MO., Green F., Conradie JD., et al. Natural antibodies to avidin in human serum. *Immunology letter*, 35: 277-280, 1993.
- Caron de Fromental C., Soussi T. TP53 tumor suppressor gene: a model for investigating human mutagenesis. *Genes Chromosomes Cancer* 1992; 4: 1–15.
- Cawley H. M., Meltzer S. J., De Benedetti V., et al. Anti-p53 antibodies in patients with Barrett's esophagus or esophageal carcinoma can predate cancer diagnosis. *Gastroenterology*, 115: 19-27, 1998.
- Crawford L.V., Piw D.C., Ulbrook R.D. Detection of antibodies against the cellular protein p53 in sera from patients with breast cancer. *Int J Cancer* 1982; 30: 403–8.
- Davidoff A.M., Iglehart J.D., Marks J.R. Immune response to p53 is dependent upon p53 HSP70 complexes in breast cancer. *Proc Natl Acad Sci USA* 1992; 89: 3439–42.
- El-Deiry W.S., Harper J.W., O'Connor P.M., et al. WAF1/ CIP1 is induced in p53-mediated G1 arrest and apoptosis. *Cancer Res* 1994; 54: 1169–74.
- El-Deiry W.S., Tokino T., Velculescu V.E., et al. WAF1, a potential mediator of p53 tumor suppression. *Cell* 1993; 75: 817–25.
- Finlay C.A., Hinds P.W., Tan T-H, Eliyahu D., et al. Activating mutations for transformation by p53 produce a gene product that forms a hsp70-p53 complex with an altered half life. *Mol Cell Biol* 1988; 8: 531-9.
- Gadducci A., Ferdeghini M., Buttitta F., et al. Serum anti-p53 antibodies in the follow-up of patients with advanced ovarian carcinoma. *Anticancer Res.*, 18: 3763-3766, 1998.
- Gire V., Wynford-Thomas D., Reinitiation of DNA synthesis and cell division in senescent human fibroblasts by microinjection of anti-p53 antibodies, *Mol. Cell. Biol.* 18 (1998) 1611–1621.

- Green J.A., Mundela B., Jenkins J., et al. Serum p53 antibodies: incidence in familial breast cancer. *Eur J Cancer* 1994; 30:580–4.
- Green J.A., Robertson B.A., Campbell I.R., et al. Expression of the p53 gene and presence of serum autoantibodies in ovarian cancer: correlation with differentiation. *Cancer Det Prev* 1995; 19: 151–5.
- Guinee D.G. Jr., Travis W.D., Trivers G.E., et al. Gender comparisons in human lung cancer: analysis of p53 mutations, anti-p53 serum antibodies and C-erbB-2 expression. *Carcinogenesis* 1995; 16: 993–1002.
- Hammel P., Boissier B., Chaumette M. T., et al. Detection and monitoring of serum p53 antibodies in patients with colorectal cancer. *Gut*, 40: 356-361, 1997.
- Hollstein M., Sidransky D., Vogelstein B., et al. p53 mutations in human cancers. *Science* 1991; 253:49–53.
- Houbiers J.G.A., Van der Burg S.H., Van de Watering L.M.G., et al. Antibodies against p53 are associated with poor prognosis of colorectal cancer. *Br J Cancer* 1995; 72: 637–41.
- Komiya T., Hirashima T., Takada M., et al. Prognostic significance of serum p53 antibodies in squamous cell carcinoma of the lung. *Anticancer Res.*, 17: 3721-3724, 1997.
- Kress M., May E., Cassingena R., et al. Simian Virus 40-transformed cells express new species of proteins precipitable by anti-simian virus 40 serum. *J. Virol.*, 31: 472-483, 1979.
- Kressner U., Glimelius B., Bergstrom R., et al. Increased serum p53 antibody levels indicate poor prognosis in patients with colorectal cancer. *Br. J. Cancer*, 77: 1848-1851, 1998.

- Labrecque S., Naor N., Thomson D., et al. Analysis of the anti-p53 antibody response in cancer patients. *Cancer Res* 1993; 53:3468–71.
- Lai C-L., Tsai C-M., Tsai T-T., et al. Presence of serum anti-p53 antibodies is associated with pleural effusion and poor prognosis in lung cancer patients. *Clin. Cancer Res.*, 4: 3025–3030, 1998.
- Lane D.P. A death in the life of p53. *Nature* 1993; 362: 786–7.
- Lane D.P. p53, Guardian of the genome. *Nature* 1992; 358: 15–6.
- Laudanski J., Burzykowski T., Niklinska W., et al. Prognostic value of serum p53 antibodies in patients with resected non-small cell lung cancer. *Lung Cancer*, 22: 191-200, 1998.
- Lenner P., Wiklund F., Emdin S. O., et al. Serum antibodies against p53 in relation to cancer risk and prognosis in breast cancer: a population-based epidemiological study. *Br. J. Cancer*, 79: 927-932, 1999.
- Levine A.J., Momand J., Finlay C.A. The p53 tumor suppressor gene. *Nature* 1991; 35: 453-6
- Lindblom, Annika and Annelie Liljegren. "Tumor Markers in Malignancies." *British Medical Journal* 320 (2000): 424.
- Lubin R., Schlichtholz B., Teillaud J. L., et al. p53 antibodies in patients with various types of cancer: assay, identification and characterization. *Clin. Cancer Res.*, 1: 1463-1469, 1995.
- Lubin R., Zalcman G., Bouchet L., et al. Serum p53 antibodies as early markers of lung cancer. *Nat. Med.*, 1: 701-702, 1995.

- Lubin, R., Schlichtholz, B., Teillaud, J. L., et al. p53 antibodies in patients with various types of cancer: assay, identification and characterization. *Clin. Cancer Res.*, 1: 1463–1469, 1995.
- Maehara Y., Kakeji Y., Watanabe A., et al. Clinical implications of serum anti-p53 antibodies for patients with gastric carcinoma. *Cancer (Phila.)*, 85: 302-308, 1999.
- Mudenda B., Green J. A., Green B., et al. The relationship between serum p53 autoantibodies and characteristics of human breast cancer. *Br. J. Cancer*, 69: 1115-1119, 1994.
- Nelson W.G., Kastan M.B. DNA strand breaks: the DNA template alterations that trigger p53-dependent DNA damage response pathways. *Mol Cell Biol* 1994; 14: 1815–23.
- Nowell P.C. The clonal evolution of tumor cell populations. *Science* 1976; 194: 23-28
- Peyrat J. P., Bonneterre J., Lubin R., et al. Prognostic significance of circulating p53 antibodies in patients undergoing surgery for locoregional breast cancer. *Lancet*, 345: 621-622, 1995.
- Polge A., Bourgaux J. F., Bancel E., et al. p53 and follow-up of colorectal adenocarcinomas. *Dig. Dis. Sci.*, 43: 1434-1442, 1998.
- Porzolt F. M. S., Hoher D., Muche D., et al. Biological relevance of auto-antibodies against p53 in patients with metastatic breast cancer. *Onkologie.*, 17: 402-408, 1994.
- Ralhan R., Nath N., Agarwal S., et al. Circulating p53 antibodies as early markers of oral cancer: correlation with p53 alterations. *Clin. Cancer Res.*, 4: 2147–2152, 1998.

- Rohayem J., Conrad K., Zimmermann T., et al. Comparison of the Diagnostic Accuracy of Three Commercially Available Enzyme Immunoassays for Anti-p53 Antibodies, *Clinical Chemistry* 1999; 45: 2014-2016.
- Romano J.W., Ehrhart J.C., Duthu A., et al. Identification and characterization of a p53 gene mutation in a human osteosarcoma cell line, *Oncogene* 4 (1989) 1483–1488.
- Rosenfeld M. R., Malats N., Schramm L., et al. Serum anti-p53 antibodies and prognosis of patients with small-cell lung cancer. *J. Natl. Cancer Inst.*, 89: 381-385, 1997.
- Saffroy R., Lelong J. C., Azoulay D., et al. Clinical significance of circulating anti-p53 antibodies in European patients with hepatocellular carcinoma. *Br. J. Cancer*, 79: 604-610, 1999.
- Salgia R., Harpole D., Herndon J. E., et al. "Role of Serum Tumor Markers CA125 and CEA in Non-small Cell Lung Cancer." *Anticancer Research* 21, no. 2 (2001).
- Saleh J., Kreissler-Haag D., Montenarh M., p53 autoantibodies from patients with colorectal cancer recognize common epitopes in the N- and C-terminus of p53, *Int. J. Oncol.* 25 (2004) 1149–1156.
- Schlichtholz B., Tredaniel J., Lubin R., et al. Analyses of p53 antibodies in sera of patients with lung carcinoma define immunodominant regions in the p53 protein. *Br. J. Cancer*, 69: 809-816, 1994.
- Schlichtholz, B., Legros, Y., Gillet, D., et al. The immune response to p53 in breast cancer patients is directed against immunodominant epitopes unrelated to the mutational hot spot. *Cancer Res.*, 52: 6380–6384, 1992.
- Shimada H., Arima M., Nakajima K., et al. "Detection of serum p53 antibodies in mucosal esophageal cancer and negative conversion after treatment" (Letter). *Am. J. Gastroenterol.*, 93: 1388-1389, 1998.

- Shiota G., Ishida M., Noguchi N., et al. Clinical significance of serum p53 antibody in patients with gastric cancer. *Res. Commun. Mol. Pathol. Pharmacol.*, 99: 41-51, 1998.
- Soussi T, Lubin R. Anti-p53 antibodies. In: Peter JB, Shoenfeld Y, eds. *Antibodies*. New York: Elsevier Science, 1996:595–9.
- Stephen C.W., Helminen P., Lane D.P., Characterisation of epitopes on human p53 using phage-displayed peptide libraries: insights into antibody–peptide interactions, *J. Mol. Biol.* 248 (1995) 58–78.
- Tavassoli M., Brunel N., Maher R., et al. p53 antibodies in the saliva of patients with squamous cell carcinoma of the oral cavity. *Int. J. Cancer*, 78: 390–391, 1998.
- Trivers G. E., Cawley H. L., Debenedetti V. M. G., et al. Anti-p53 antibodies in sera of workers occupationally exposed to vinyl chloride. *J. Natl. Cancer Inst.*, 87: 1400-1407, 1995.
- Vojtesek B., Ba'rtrek J., Midgley C.A., et al. An immunochemical analysis of the human nuclear phosphoprotein p53. New monoclonal antibodies and epitope mapping using recombinant p53, *J. Immunol. Methods* 151 (1992) 237–244.
- Volkman M., Muller M., Hofmann W.J., et al. The humoral immune response to p53 in patients with hepatocellular carcinoma is specific for malignancy and independent of the alpha-fetoprotein status. *Hepatology* 1993; 18:559–65.
- Brevern M. C., Hollstein M. C., Cawley H. M., et al. Circulating anti-p53 antibodies in esophageal cancer patients are found predominantly in individuals with p53 core domain mutations in their tumors. *Cancer Res.*, 56: 4917-4921, 1996.

- Werner J. A., Gottschlich S., Folz B. J., et al. p53 serum antibodies as prognostic indicator in head and neck cancer. *Cancer Immunol. Immunother.*, 44: 112-116, 1997.
- Wild C.P., Ridanpaa M., Anttila S., et al. p53 antibodies in the sera of lung cancer patients: comparison with p53 mutation in the tumor tissue. *Int J Cancer* 1995; 64: 176-81.
- Willsher P. C., Pinder S. E., Robertson L., et al. The significance of p53 autoantibodies in the serum of patients with breast cancer. *Anticancer Res.*, 16: 927-930, 1996.
- Winter S.F., Minna J.D., Johnson B.E., et al. Development of antibodies against p53 in lung cancer patients appears to be dependent on the p53 mutation. *Cancer Res* 1992; 52: 4168-74.
- Wu C. W., Lin Y. Y., Chen G. D., et al. Serum anti-p53 antibodies in gastric adenocarcinoma patients are associated with poor prognosis, lymph node metastasis and poorly differentiated nuclear grade. *Br. J. Cancer*, 80: 483-488, 1999.
- Wu C., James T., and Robert M. Makamura. *Human Circulating Tumor Markers: Current Concepts and Clinical Applications*. Chicago: American Society of Clinical Pathologists Press (ASCP) Press, 1997.
- Yewdell J.W., Gannon J.V., Lane D.P., Monoclonal antibody analysis of p53 expression in normal and transformed cells, *J. Virol.* 59 (1986) 444-452.
- Zalcman G., Schlichtholz B., Trédaniel J., et al. Monitoring of p53 auto antibodies in lung cancer during therapy: relationship to response to treatment. *Clin. Cancer Res.*, 4: 1359-1366, 1998.
- Zalcman G., Trédaniel G., Schlichtholz B., et al. Prognostic significance of serum p53 antibody in patients with limited-stage small cell lung cancer. *Int. J. Cancer*, 89: 81-86, 2000.